Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.26% | -5.67% | -6.87% | -11.80% | -19.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.90% | 35.97% | 18.92% | -19.47% | -38.17% |
| Operating Income | -47.90% | -35.97% | -18.92% | 19.47% | 38.17% |
| Income Before Tax | 13.06% | 66.16% | 71.53% | 73.38% | 71.74% |
| Income Tax Expenses | -74.62% | 68.72% | 72.95% | 76.36% | 80.80% |
| Earnings from Continuing Operations | 25.56% | 65.52% | 71.18% | 72.70% | 69.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.56% | 65.52% | 71.18% | 72.70% | 69.71% |
| EBIT | -47.90% | -35.97% | -18.92% | 19.47% | 38.17% |
| EBITDA | -47.99% | -36.12% | -19.12% | 19.11% | 37.42% |
| EPS Basic | 41.49% | 76.81% | 81.02% | 79.39% | 74.34% |
| Normalized Basic EPS | 22.46% | 12.29% | 36.67% | 36.74% | 40.57% |
| EPS Diluted | 41.46% | 76.80% | 81.01% | 79.38% | 74.34% |
| Normalized Diluted EPS | 22.46% | 12.29% | 36.67% | 36.74% | 40.57% |
| Average Basic Shares Outstanding | 25.76% | 33.68% | 51.87% | 39.24% | 27.72% |
| Average Diluted Shares Outstanding | 25.76% | 33.68% | 51.87% | 39.24% | 27.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |